

Abstract

Vaccines capable of eliciting an immune
antitumor response for prostate tumors are disclosed. The
active ingredient in such vaccines is selected from the
5 group consisting of

at least one antigen over-represented in the
prostate gland or an immunologically effective portion
thereof;

an expression system capable of generating in
10 situ said antigen or portion;
a naked DNA encoding said antigen or portion;
and

an antiidiotypic antibody or fragment thereof
which mimics said antigen or portion.

04370320-1